PerouC.M., SorlieT., EisenM.B.. Molecular portraits of human breast tumours. Nature2000; 406: 747–52.
2.
AasT., BorresenA.L., GeislerS.. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med1996; 2: 811–4.
3.
GeislerS., LonningP.E., AasT.. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res2001; 61: 2505–12.
4.
SorlieT., PerouC.M., TibshiraniR.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA2001; 98: 10869–74.
5.
van't VeerL.J., DaiH., van de VijverM.J.. Gene expression profiling predicts clinical outcome of breast cancer. Nature2002; 415: 530–6.
6.
BorresenA.L., AndersenT.I., EyfjordJ.E.. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer1995; 14: 71–5.
7.
PollackJ.R., SorlieT., PerouC.M.. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA2002; 99: 12963–8.
